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Invited Commentary
Adverse Cognitive Effects ofMedications
Turning Attention to Reversibility
Noll L. Campbell, PharmD; Malaz A. Boustani, MD, MPH
In this issue of JAMA InternalMedicine, Gray and colleagues1
present findings from an observational analysis that show a
higher risk for dementia with the increasing dose and dura-
tion of exposure to medica-
tions with strong anticholin-
ergic activity. The risk for
dementia was consistent
when comparing participants with recent and past heavy use
of such medications with nonusers, suggesting that the ad-
verse cognitive effects are permanent. Other studies2-4 have
consistently shown similar results. However, the question of
reversibilityof theadversecognitiveeffectsofmedicationsand
the safety risks of discontinuing the use of such medications
remain untested in randomized clinical trials (RCTs).
Gray and colleagues1 paid special attention to reducing
several sources of bias, including recall bias, by defining
medication exposure through dispensing records. They also
addressed protopathic bias and confounding by indication
by excluding anticholinergic exposure in the year before the
outcome assessment and by adjusting for prodromal symp-
toms of dementia. Finally, the investigators used the clinical
diagnosis of dementia derived from a consensus panel of
experts as the dependent cognitive variable of interest. The
clinical diagnosis of dementia has become the preferred
method of identifying cognitive impairment in pharmaco-
epidemiologic studies because it represents cognitive
decline that affects daily activities and is not owing to an
otherwise reversible cause.2,3
In addition to anticholinergics, the American Geriatrics
Society has also recognized benzodiazepines and histamine
receptor2 antagonists as potentially inappropriate for older
adults owing to their adverse cognitive effects.5,6 Gray and
colleagues1 report that 78.3% of their cohort were dispensed
at least 1 strong anticholinergic in the 10-year study period.
Castelino and colleagues7 have also reported that as many as
60% of ambulatory older adults use at least 1 medication
with adverse cognitive effects. The methods used by Gray
and colleagues should be repeated to determine the risk for
cognitive impairment conferred by all medications with
adverse cognitive effects, not only anticholinergics, within
healthy older adults and older adults with multiple chronic
conditions.
Our group2,3 previously found an association between
exposure to anticholinergics and the clinical diagnosis of
cognitive impairment (mild cognitive impairment or demen-
tia). The investigators used 1 year of dispensing data as the
independent variable and found results similar to those of
Gray and colleagues,1 suggesting a 2-fold increased risk for a
clinical diagnosis of mild cognitive impairment or dementia
among those using strong anticholinergics for at least 60
days in a 1-year period.3 Those findings showed a stronger
association with the diagnosis of mild cognitive impairment
than dementia, suggesting the possibility of a reversible
effect. The findings by Gray and colleagues provide the alter-
native hypothesis that the adverse cognitive effect of anti-
cholinergics may be permanent.
The question of reversibility of the adverse cognitive ef-
fects ofmedications is of significant importance for the aging
population and thehealth care system.The current burdenof
dementia (5 million people in the United States in 2013) rep-
resents an estimated $214 billion in costs of care.8 With the
growthof theagingpopulation, theanticipatednumberofolder
adultswithdementia is expected tobe 16millionby2050,with
$1.2 trillion expected in costs of care.8 Although a number of
pharmacologic agents arebeing investigated to reduce thebur-
denof or topreventdementia, nomedication-based interven-
tion is currently available to prevent dementia.
Therefore, reversing the adverse cognitive effects of
medications such as anticholinergics is an important inter-
vention that may attenuate the expected increasing burden
of dementia. It makes clinical sense to minimize exposure to
these medications among older adults; however, no evi-
dence from RCTs supports the hypothesis that discontinuing
these medication therapies improves cognition. Although
studies have shown that reducing exposure to medications
with adverse cognitive effects can be accomplished success-
fully in ambulatory older adults, the effect on cognition
remains insufficiently studied.
SuchanRCTmustbe conductednotonly todetermine the
effect on cognition but also to determine the safety and un-
intended consequences of discontinuing medication thera-
pies amongolder adults. Because the approach todiscontinu-
ing such awide array ofmedication therapies depends on the
dose,duration,and indication (eg,meclizine fordizziness, ami-
triptyline for depressionor neuropathy, and lorazepam for in-
somnia), the intervention must be designed with the ability
to tailor the deprescribing and monitoring approach to each
individual to optimize safe andeffectivemedication changes.
Only with results from such RCTs will we be able to translate
findings from observational cohort studies into interven-
tions to minimize the adverse cognitive effects of medica-
tions. Last, although an RCT would require a few years to be
conducted, a successful intervention would be available for
clinical use in a significantly shorter period than the 17 years
required for thedevelopment, testing, andapproval of anovel
pharmacologic agent.
We therefore applaud theworkbyGrayandcolleagues1 for
the novel approach of describing the cumulative risk for de-
mentia amongusers ofmedicationswith adverse cognitive ef-
fects; however, we emphasize that translation of these find-
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ings into clinical interventions is an important next stepwith
the potential for a meaningful effect on the quality of care of
older adults and the global burden of dementia. Results from
observational studies heighten the need to develop interven-
tions to identify and attenuate potentially reversible risk fac-
tors for dementia among older adults.
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